The Zhitong Finance App learned that Hengrui Pharmaceutical (01276) rose by more than 3%. As of press release, it had risen 2.97% to HK$47.8, with a turnover of HK$41.391 million.

According to the news, Hengrui Pharmaceutical announced that recently, Beijing Shengdi Pharmaceutical Co., Ltd., a subsidiary of Jiangsu Hengrui Pharmaceutical Co., Ltd. (hereinafter referred to as the “Company”), received approval from the State Drug Administration (hereinafter referred to as the “State Drug Administration”) to issue a “Drug Clinical Trial Approval Notice” for SHR-3201 injections and will conduct clinical trials in the near future.

SHR-3201 injection is a drug independently developed by the company to treat Alzheimer's disease (AD). It can remove biomarkers of the disease in the patient's brain and delay the patient's cognitive decline. According to inquiries, no similar drugs have been approved for marketing at home or abroad. Up to now, the total R&D investment for SHR-3201 injection-related projects is approximately RMB 48.8 million (unaudited).

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.